XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology
January 17, 2017 08:00 ET
|
XBiotech, Inc
AUSTIN, Texas, Jan. 17, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced the publication of results from its pivotal phase 3 trial of the Company’s lead monoclonal antibody...
XBiotech Completes Enrollment in Global Phase III Study using Xilonix Monotherapy to Treat Advanced Colorectal Cancer
December 07, 2016 08:00 ET
|
XBiotech, Inc
AUSTIN, Texas, Dec. 07, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, today announced that enrollment has been completed in its randomized,...
XBiotech Completes Enrollment in Global Phase I/II Study for its True Human™ Antibody Treatment for Serious Staphylococcus aureus Infections
December 06, 2016 08:00 ET
|
XBiotech, Inc
AUSTIN, Texas, Dec. 06, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, today announced that enrollment has been completed in its randomized,...
XBiotech Announces Research Collaboration with Renowned Gastroenterologist
November 17, 2016 08:18 ET
|
XBiotech, Inc
XBiotech's True Human antibodies Targeting IL-1 alpha (IL-1alpha) to be used in Researching Treatment for Inflammatory Bowel Disease (IBD) AUSTIN, Texas, Nov. 17, 2016 (GLOBE NEWSWIRE) --...
XBiotech to Provide Third Quarter 2016 Business Update on November 15
November 10, 2016 08:00 ET
|
XBiotech, Inc
AUSTIN, Texas, Nov. 10, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, announced today that it will host a live conference call and webcast...
XBiotech Announces Successful Completion of EMA GMP Inspection
October 12, 2016 09:10 ET
|
XBiotech, Inc
AUSTIN, Texas, Oct. 12, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ therapeutic antibodies, today announced a successful GMP (Good Manufacturing...
XBiotech Announces Dismissal of Class Action Lawsuit in Texas
October 11, 2016 08:00 ET
|
XBiotech, Inc
AUSTIN, Texas, Oct. 11, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ therapeutic antibodies, today announced that the U.S. District Court for the...
XBiotech Announces Grand Opening Date for New Commercial Manufacturing Facility
August 22, 2016 15:05 ET
|
XBiotech, Inc
AUSTIN, Texas, Aug. 22, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ therapeutic antibodies, today announced the timing for the grand opening of...
XBiotech to Provide Second Quarter 2016 Business Update on August 16
August 10, 2016 08:00 ET
|
XBiotech, Inc
AUSTIN, Texas, Aug. 10, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, announced today that it will host a live conference call and webcast...
XBiotech Provides Update on Xilonix™ Phase III Programs in US and EU
July 22, 2016 18:45 ET
|
XBiotech, Inc
AUSTIN, Texas, July 22, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ antibody therapies, said today that the Independent Data Monitoring Committee...